Skip Navigation.

Site Map.

Help.

Account.

Cart.

Home

This Web site is a component of the SAMHSA Health Information Network.

Quick Find & Order

Top 50

Pubs in Series

Cost Recovery Items

Posters

Videos

Spanish

Drugs

Audiences

Issues

Publications Home

NCADI Home

This Web site is a component of the SAMHSA Health Information Network.

Treatment for HIV-Infected Alcohol and Other Drug Abusers
Treatment Improvement Protocol (TIP) Series: 15

Appendix A -- Bibliography

Multiple entries by authors arranged by date.

Aboulker, J.P., and Swart, A.M.: Preliminary analysis of the Concorde trial. Concorde Coordinating Committee (letter). Lancet 341(8849):889-890, 1993.

Abrams, D.I., Goldman, A.I., Launer, C., Korvick, J.A., et al.: A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. New England Journal of Medicine 330(10):657-662, 1994.

Advisory Group on HIV Early Intervention.: Human immunodeficiency virus early intervention physician guidelines. Archives of Family Medicine 3(11):988-1002, 1994.

Agency for Health Care Policy and Research.: Managing early HIV infection. Early HIV Infection Guideline Panel. American Family Physician 49(4):801-814, 1994.

American Academy of Neurology, AIDS Task Force.: Criteria for diagnosis of HIV-1 associated dementia complex: nomenclature and research case definitions for neurologic manifestations of HIV-1 infection. Neurology 41:778-784, 1991.

American Psychiatric Association.: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.

American Society of Addiction Medicine.: AIDS Guidelines for Facilities. Washington, D.C.: American Society of Addiction Medicine, 1991.

Avins, A.L., Woods, W.J., Lindan, C.P., Hudes, E.S., et al.: HIV infection and risk behaviors among heterosexuals in alcohol treatment programs. Journal of the American Medical Association 271(7):515-518, 1994.

Ball, J.C., Lange, W.R., Myers, C.P., and Friedman S.R.: Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior 29(3):214-226, 1988.

Barnes, P.F., Bloch, A.B., Davidson, P.T., and Snider, D.E., Jr.: Tuberculosis in patients with human immunodeficiency virus infection. New England Journal of Medicine 324(23):1644-1650, 1991.

Bass, J.B., Jr., Farer, L.S., Hopewell, P.C., O'Brien, R., et al.: Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. American Journal of Respiratory and Critical Care Medicine 149(5):1359-1374, 1994.

Batki, S.L., London, J., Ferrando, S.J., Pattillo, J., et al.: Psychiatric disorders and drug use in 100 HIV-infected IVDUs. In: Harris, L.S., ed. Problems of Drug Dependence 1991: Proceeding of the 53rd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph 119. DHHS Publication No. (ADM) 92-1888. Rockville, Maryland: National Institute on Drug Abuse, 1992. p. 319.

Batki, S.L., and London, J.: Drug abuse treatment for HIV-infected patients. In: Sorensen, J.L., Wermouth, L.A., Gibson, D.R., Choi, K.-H., et al, eds. Preventing AIDS in Drug Users and Their Sexual Partners. New York: Guilford Press, 1991. pp. 77-98.

Batki, S.L.: Buspirone in drug users with AIDS or AIDS-related complex. Journal of Clinical Psychopharmacology 10(3 Suppl.):111S-115S, 1990a.

Batki, S.L.: Drug abuse, psychiatric disorders, and AIDS. Dual and triple diagnosis. Western Journal of Medicine (Special issue on addiction medicine) 152(5):547-552, 1990b.

Batki, S.L.: Treatment of intravenous drug users with AIDS: the role of methadone maintenance. Journal of Psychoactive Drugs 20(2):213-216, 1988.

Batki, S.L., ~~Sorenson,~~ Sorensen, J.L., Faltz, B., and Madover, S.: Psychiatric aspects of treatment of i.v. drug abusers with AIDS. Hospital and Community Psychiatry 39(4):439-441, 1988.

Beck, A.T.: Beck Depression Inventory. San Antonio, Texas: Psychological Corporation, 1993.

Boccellari, A.A., Dilley, J.W., Chambers, D.B., Yingling, C.D., et al.: Immune function and neuropsychological performance in HIV-1-infected homosexual men. Journal of Acquired Immune Deficiency Syndrome 6(6):592-601, 1993a.; Relationship of CD4 counts to neurophysiological function in HIV-1 infected homosexual men. Archives of Neurology 50(5):517-521, 1993b.

Booth, R.E., Watters, J.K., and Chitwood, D.D.: HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. American Journal of Public Health 83(8):1144-1148, 1993.

Bowen, G.S., Marconi, K., Kohn, S., Bailey, D.M., et al.: First year of AIDS services delivery under Title I of the Ryan White CARE Act. Public Health Reports 107(5):491-499, 1992.

Boyer, P.J., Dillon, M., Navaie, M., Deveikis, A., et al.: Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. Journal of the American Medical Association 271(24):1925-1930, 1994.

Brickner, P.W., Torres, R.A., Barnes, M., Newman, R.G., et al.: Recommendations for control and prevention of human immunodeficiency virus (HIV) infection in intravenous drug users. Annals of Internal Medicine 110(10):833-837, 1989.

Broder, S., Merigan, T.C., Jr., and Bolognesi, D., eds.: Textbook of AIDS Medicine. Baltimore: Williams & Wilkins, 1994.

Broers B., Morabia A., and Hirschel, B.: A cohort study of drug users' compliance with zidovudine treatment. Archives of Internal Medicine 154(10):1121-1127, 1994.

Brown, B.S.: AIDS and the provision of drug user treatment. International Journal of the Addictions 25(12A):1503-1514, 1990-91.

Cabaj, R.P.: AIDS and chemical dependency: special issues and treatment barriers for gay and bisexual men. Journal of Psychoactive Drugs 21(4):387-393, 1989.

Cameron, W., Sparti, P., Pietroski, N., et al.: Rifabutin therapy for the prevention of MAC bacteremia in patients with AIDS and CD4 #200. Eighth International Conference on AIDS. Amsterdam, July 1992.

Center for Substance Abuse Treatment.: Treatment for Alcohol and Other Drug Abuse. Opportunities for Collaboration. Technical Assistance Publication Series 11. DHHS Publication No. (SMA) 94-2075. Rockville, Maryland: 1994.

Centers for Disease Control and Prevention.: Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morbidity and Mortality Weekly Report 43(RR-11):1-20, 1994a.

Centers for Disease Control and Prevention.: Guidelines for preventing the transmission of mycobacterium tuberculosis in health-care facilities. Federal Register 59(208):54242-54303, 1994b.

Centers for Disease Control and Prevention.: Zidovudine for the prevention of HIV transmission from mother to infant. Morbidity and Mortality Weekly Report 43(16):285-287, 1994c.

Centers for Disease Control and Prevention.: National HIV seroprevalence survey, 1992. Washington, D.C., U.S. Government Printing Office, 1993a.

Centers for Disease Control and Prevention.: HIV/AIDS Surveillance Report. Atlanta: Centers for Disease Control and Prevention, 1993b.

Centers for Disease Control and Prevention.: Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. Morbidity and Mortality Weekly Report 42(RR-4):1-18, 1993c.

Centers for Disease Control and Prevention.: Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Morbidity and Mortality Weekly Report 42(RR-9):14-20, 1993d.

Centers for Disease Control and Prevention.: 1993 sexually transmitted diseases treatment guidelines. Morbidity and Mortality Weekly Report 42(RR-14):1-102, 1993e.

Centers for Disease Control and Prevention.: Technical guidance on HIV counseling. Morbidity and Mortality Weekly Report 42(RR-2):11-17, 1993f.

Centers for Disease Control and Prevention.: Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. Morbidity and Mortality Weekly Report 41(RR-4):1-11, 1992.

Centers for Disease Control and Prevention.: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 41(RR-17):1-19, 1992a.

Centers for Disease Control and Prevention.: National action plan to combat multidrug-resistant tuberculosis. Morbidity and Mortality Weekly Report 41(RR-11):5-48, 1992b.

Centers for Disease Control and Prevention.: Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons -- Florida and New York 1988-1991. Morbidity and Mortality Weekly Report 40(34):585-591, 1991a.

Centers for Disease Control and Prevention.: Purified protein derivative (PPD) Ctuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morbidity and Mortality Weekly Report 40(RR-5):27-32, 1991b.

Centers for Disease Control and Prevention.: Screening for tuberculosis and tuberculous infection in high-risk populations. Recommendations of the Advisory Committee for the Elimination of Tuberculosis. Morbidity and Mortality Weekly Report 39(RR-8):1-7, 1990.

Centers for Disease Control and Prevention.: Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). Morbidity and Mortality Weekly Report 38(14):236-238,243-250, 1989.

Centers for Disease Control and Prevention.: Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. Morbidity and Mortality Weekly Report 37(24):377-382, 387-388, 1988.

Centers for Disease Control and Prevention.: Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. Morbidity and Mortality Weekly Report 36(31):509-515, 1987a.

Centers for Disease Control and Prevention.: Recommendations for prevention of HIV transmission in health-care settings. Morbidity and Mortality Weekly Report 36(Suppl. 2):1S-18S, 1987b.

Chaisson, R.E., Bacchetti, P., Osmond, D., Brodie, B., et al.: Cocaine use and HIV infection in intravenous drug users in San Francisco. Journal of the American Medical Association 261(4):561-565, 1989.

Chiasson, M.A., Stoneburner, R.L., Hildebrandt, D.S., Ewing, W.E., et al.: Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). AIDS 5(9):1121-1126, 1991.

Chirgwin, K., DeHovitz, J.A., Dillon, S., and McCormack, W.M.: HIV infection, genital ulcer disease, and crack cocaine use among patients attending a clinic for sexually transmitted diseases. American Journal of Public Health 81(12):1576-1579, 1991.

Clark, S.J., Saag, M.S., Decker, W.D., Campbell-Hill, S., et al.: High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. New England Journal of Medicine 324(14):954-960, 1991.

Collier, A.C., Coombs, R.W., Fischl, M.A., Skolnik, P.R., et al.: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Annals of Internal Medicine 119(8):786-793, 1993.

Cooper, D.A., Gatell, J.M., Kroon, S., Clumeck, N., et al.: Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. New England Journal of Medicine 329(5):297-303, 1993.

Cooper, J.R.: Methadone treatment and acquired immunodeficiency syndrome. Journal of the American Medical Association 262(12):1664-1668, 1989.

Crane, L.R., Levine, D.P., Zervos, M.J., and Cummings, G.: Bacteremia in narcotic addicts at the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric therapy. Review of Infectious Diseases 8(3):364-373, 1986.

Daley, C.L., Small, P.M., Schecter, G.F., Schoolnik, G.K., et al.: An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. New England Journal of Medicine 326(4):231-235, 1992.

Dalton, H.L.: AIDS in blackface. Daedalus: Journal of the American Academy of Arts and Sciences 118(3):205-227, 1989.

DeHovitz, J.A., and Sadovsky, R.: Initial clinical assessment and management of HIV infection. Primary Care (Special issue: AIDS and HIV Infection in Office Practice) 19(1):35-56, 1992.

DePhilippis, D., Metzger, D.S., Woody, G.E., and Navaline, H.A.: Attitudes toward mandatory human immunodeficiency virus testing and contact tracing. A survey of intravenous drug users in treatment. Journal of Substance Abuse Treatment 9(1):39-42, 1992.

Des Jarlais, D.C., and Friedman, S.R.: AIDS and the use of injected drugs. Scientific American February 1994a, pp. 82-88.

Des Jarlais, D.C., Friedman, S.R., Sotheran, J.L., Wenston, J., et al.: Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. Journal of the American Medical Association 271(2):121-127, 1994b.

Donahue, J.G., Nelson, K.E., Munoz, A., Vlahov, D., et al.: Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. American Journal of Epidemiology 134(10):1206-1211, 1991.

Donoghoe, M.C., Stimson, G.V., and Dolan, K.A.: Syringe Exchange in England: An Overview. London: Tufnell Press, 1992.

Drucker, E.: Epidemic in the war zone: AIDS and community survival in New York City. International Journal of Health Services 20(4):601-615, 1990.

Esteban, J.I., Esteban, R., Vilamodiu, L., Lopez-Talavera, J.C., et al.: Hepatitis C virus antibodies among risk groups in Spain. Lancet 2(8658):294-297, 1989.

Farley, T.A., Cartter, M.L., Wassell, J.T., and Hadler, J.L.: Predictors of outcome in methadone programs: effect of HIV counseling and testing. AIDS 6(1):115-121, 1992.

Fauci, A.A.: Multifactorial value of HIV disease: implications for therapy. Science 262:1011-1018, 1993.

Fernandez, F.: Psychopharmacological interventions in HIV infections. New Directions in Mental Health Services 48:43-53, 1990.

Fernandez, F., Holmes, V.F., Levy, J.K., and Ruiz, P.: Consultation-liaison psychiatry and HIV-related disorders. Hospital and Community Psychiatry 40(2):146-153, 1989.

Ferrando, S.J., and Batki, S.L.: HIV-infected intravenous drug users in methadone maintenance treatment: clinical problems and their management. Journal of Psychoactive Drugs 23(2):217-224, 1991.

Fischl, M.A., Daikos, G.L., Uttamchandani, R.B., Poblete, R.B., et al.: Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Annals of Internal Medicine 117(3):184-190, 1992a.

Fischl, M.A., Uttamchandani, R.B., Daikos, G.L., Poblete, R.B., et al.: An outbreak of tuberculosis caused by multiple-drug-resistant tubercule bacilli among patients with HIV infection. Annals of Internal Medicine 117(3):177-183, 1992b.

Fischl, M.A., Richman, D.D., Hansen, N., Collier, A.C., et al.: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Annals of Internal Medicine 112(10):721-730, 1990.

Fischl, M.A., Richman, D.D., Grieco, M.H., Gottlieb, M.S., et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine 317(4):185-191, 1987.

Folstein, M.F., Folstein, S.E., and McHugh, P.R.: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12(3):189-198, 1975.

Forstein, M.: The neuropsychiatric aspects of HIV infection. Primary Care (Special issue: AIDS and HIV Infection in Office Practice) 19(1):97-117, 1992.

Gallant, J.E., Moore, R.D., and Chaisson, R.E.: Prophylaxis for opportunistic infections in patients with HIV infection. Annals of Internal Medicine 120 (11):932-944, 1994.

Gerbert, B., Maguire, B.T., Bleeker, T., Coates, T.J., et al.: Primary care physicians and AIDS. Attitudinal and structural barriers to care. Journal of the American Medical Association 266(20):2837-2842, 1991.

Girard, P.M., Landman, R., Gaudebout, C., Olivares, R., et al.: Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prohphylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. New England Journal of Medicine 328(21):1514-1520, 1993.

Glassroth, J., Jordan, M., Wallace, J.M., Kvale, P.A., et al.: Use of preventive interventions by persons infected with type-1 human immunodeficiency virus (HIV-1). The Pulmonary Complications of HIV Study Group. American Journal of Preventive Medicine 10(5):259-266, 1994.

Gorbach, S.L., Knox, T.A., and Roubenoff, R.: Interactions between nutrition and infection with human immunodeficiency virus. Nutrition Review 51(8):226-234, 1993.

Graham, N.M., Zeger, S.L., Park, L.P., Vermund, S.H., et al.: The effects on survival of early treatment of human immunodeficiency virus infection. New England Journal of Medicine 326(16):1037-1042, 1992.

Graham, N.M., Zeger, S.L., Park, L.P., Phair, J.P., et al.: Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS. The Multicenter AIDS Cohort Study. Lancet 338(8762):265-269, 1991.

Hahn, R.A., Onorato, I.M., Jones, T.S., and Dougherty, J.: Prevalence of HIV infection among intravenous drug users in the United States. Journal of the American Medical Association 261(18):2677-2684, 1989.

Hamilton, J.D., Hartigan, P.M., Simberkoff, M.S., Day, P.L., et al.: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. New England Journal of Medicine 326(7):437-443, 1992b.

Hartel, D.M., Schoenbaum, E.E., Selwyn, P.A., Kline, J., et al.: Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. American Journal of Public Health 85(1):83-88, 1995.

Hartel, D.M., Selwyn, P.A., Schoenbaum, E.E., et al.: Methadone maintenance treatment and reduced risk of AIDS and AIDS-specific mortality in intravenous drug users (abstract no. 8546). Fourth International Conference on AIDS. Stockholm, Sweden, June 1988.

Hartigan, P.M., Hamilton, J.D., and Simberkoff, M.S.: Early zidovudine and survival in HIV infection. The Veterans Affairs AIDS Cooperative Studies Group (letter, comment). New England Journal of Medicine 327(11):814-815; discussion 815-816, 1992.

Hecht, F.M., and Soloway, B.: HIV infection: a primary care approach. Reprints from AIDS Clinical Care Newsletter. Boston: Massachusetts Medical Society, 1992 and 1993.

Higgins, D.L., Galavotti, C., O'Reilly, K.R., Schnell, D.J., et al.: Evidence for the effects of HIV antibody counseling and testing on risk behaviors. Journal of the American Medical Association 266(17):2419-2429, 1991.

Hoover, D.R., Saah, A.J., Bacellar, H., Phair, J., et al.: Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. New England Journal of Medicine 329(26):1922-1926, 1993.

Hughes, C.P., Berg, L., Danziger, W.L., Cohen, L.A., et al.: A new clinical scale for the staging of dementia. British Journal of Psychiatry 140:566-572, 1982.

~~Iguchi, M.Y., Watters, J., Biernacki, P., McCoy, C.B., et al.~~: Update: reducing HIV transmission in intravenous-drug users not in drug treatment -- United States. Morbidity and Mortality Weekly Report 39(31):529, 535-538, 1990.

Jewett, J.F., and Hecht, F.M.: Preventive health care for adults with HIV infection. Journal of the American Medical Association 269(9):1144-1153, 1993.

Jones, P., Hamilton, P.J., Oxley, A., Codd, A., et al.: Anti-HTLV-III positive laboratory reagents (letter). Lancet 1(8443):1458-1459, 1985.

Kanof, P.D., Aronson, M.J., and Ness, R.: Organic mood syndrome associated with detoxification from methadone maintenance. American Journal of Psychiatry 150(3):423-428, 1993.

Karan, L.D.: Primary care for AIDS and chemical dependence. Western Journal of Medicine 152(5):538-542, 1990.

~~Khabazz, R.F.,~~ Khabbaz, R.F., Onorato, I.M., Cannon, R.O., Hartley, T.M., et al.: Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. New England Journal of Medicine 326(6):375-380, 1992.

Kosten, T.R.: Client issues in drug abuse treatment: addressing multiple drug use. In: Pickens, R.W., Leukefeld, C.G., and Schuster, C.R., eds. Improving Drug Abuse Treatment. NIDA Research Monograph 106. DHHS Publication No. (ADM) 91-1754. Rockville, Maryland: National Institute on Drug Abuse, 1991. pp. 136-151.

Kreek, M.J., Garfield, J.W., Gutjahr, C.L., and Giusti, L.M.: Rifampin-induced methadone withdrawal. New England Journal of Medicine 294(20):1104-1106, 1976.

Krogsgaard, K., Lindhardt, B.O., Nielson, J.O., Andersson, P., et al.: The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology 7(1):37-41, 1987.

Lampinen, T.M.: Cost-effectiveness of drug abuse treatment for primary prevention of acquired immunodeficiency syndrome: epidemiologic considerations. In: Cartwright, W.S., and Kaple, J.M., eds. Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment. NIDA Research Monograph 113. DHHS Publication No. (ADM) 91-1823. Rockville, Maryland: National Institute on Drug Abuse, 1991. pp. 114-128.

Legal Action Center.: Confidentiality: A Guide to the Federal Laws and Regulations. New York: Legal Action Center, 1991.

Libman, H., Samet, J.H., Freedberg, K.A., Jain, M., et al.: Referral to the community for continuing medical care of newly identified patients with human immunodeficiency virus infection: experience from a diagnostic evaluation unit. Clinical Research 40:586A, 1992.

Libman, H., and Witzburg, R.A., eds.: HIV Infection: A Clinical Manual, 2nd ed. Boston: Little, Brown, 1993.

Lowinson, J.H., Marion, I.J., Joseph, H., and Dole, V.P.: Methadone maintenance. In Lowinson, J.H., Ruiz, P., and Millman, R.B., eds. Substance Abuse: A Comprehensive Textbook. Baltimore: Williams & Wilkins, 1992. pp. 550-561.

Lundgren, J.D., Phillips, A.N., Pedersen, C., Clumeck, N., et al.: Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. Journal of the American Medical Association 271(14):1088-1092, 1994.

Lurie, P., Reingold, A.L., Bowser, B.J., et al.: The Public Health Impact of Needle Exchange Programs in the United States and Abroad: Summary, Conclusions, and Recommendations. Centers for Disease Control and Prevention, October, 1993.

Lyketsos, C.G., Hanson, A.L., Fishman, M., Rosenblatt, A., et al.: Manic syndrome early and late in the course of HIV. American Journal of Psychiatry 150(2):326-327, 1993.

Margolick, J.B., Munoz, A., Vlahov, D., Solomon, L., et al.: Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. Journal of the American Medical Association 267(12):1631-1636, 1992.

Marin, G.: AIDS prevention among Hispanics: needs, risk behaviors, and cultural values. Public Health Reports 104(5):411-415, 1989.

Massing, M.: The rehabbing of America. New York Times Review of Books. January 24, 1993, pp. 10-12.

McLellan, A.T., Arndt, I.O., Metzger, D.S., Woody, G.E., et al.: The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association 269(15):1953-1959, 1993.

Metzger, D.S., Woody, G.E., McLellan, A.T., O'Brien, C.P., et al.: Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndrome 6(9):1049-1056, 1993.

Minnesota Department of Human Services.: HIV-1 Guidelines for Chemical Dependency Treatment and Care Programs in Minnesota (updated 1992). St. Paul: Minnesota Department of Human Services, 1992.

Mirin, S.M., Weiss, R.D., Michael, J., and Griffin, M.L.: Psychopathology in substance abusers: diagnosis and treatment. American Journal of Drug and Alcohol Abuse 14(2):139-157, 1988.

Moore, R.D., Hidalgo, J., Sugland, B.W., and Chaisson, R.E.: Zidovudine and the natural history of the acquired immunodeficiency syndrome. New England Journal of Medicine 324(20):1412-1416, 1991.

Moreno, S., Baraia-Etxaburu, J., Bouza, E., Parras, F., et al.: Risk for developing tuberculosis among anergic patients infected with HIV. Annals of Internal Medicine 119(3):194-198, 1993.

Moss, A.R., and Bacchetti, P.: Natural history of HIV infection (published erratum appears in AIDS 3(7): following page A100). AIDS 3(2):55-61, 1989.

Moss, A.R., Vranizan, K., Gorter, R., Bacchetti, P., et al.: HIV seroconversion in intravenous drug users in San Francisco; 1985-1990. AIDS 8(2):223-231, 1994.

Musher, D.M., Hamill, R.J., and Baughn, R.E.: Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Annals of Internal Medicine 113(11):872-881, 1990.

National AIDS Network. Dually diagnosed present multiple challenges to service providers.: NAN Multi-Cultural Notes on AIDS Education and Service 3(2):1-7, 1990.

National Commission on AIDS, Working Group on Social/Human Issues: 1991.

National Institute of Allergy and Infectious Diseases.: State-of-the-art conference on azidothymidine therapy for early HIV infection. American Journal of Medicine 89(3):335-344, 1990.

New York State Department of Health, AIDS Institute.: Protocols for the Medical Care of HIV Infection. Albany: Department of Health, 1992.

Nightingale, S.D., Cameron, D.W., Gordin, F.M., Sullam, P.M., et al.: Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infections in AIDS. New England Journal of Medicine 329(12):828-833, 1993.

Northfelt, D.W.: Evaluation and treatment of later manifestations of HIV infection. Primary Care (Special issue: AIDS and HIV Infection in Office Practice) 19(1):57-85, 1992.

Novick, D.M., and Ness, G.L.: Abuse of antibiotics by abusers of parenteral heroin or cocaine. Southern Medical Journal 77(3):302-303, 1984.

O'Brien, T.R., George, J.R., and Holmberg, S.D.: Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. Journal of the American Medical Association 267(20):2775-2779, 1992.

Occupational Safety and Health Administration.: Controlling Occupational Exposure to Bloodborne Pathogens in Dentistry. Washington, D.C.: OSHA, 1992.

O'Connor, P.G., Selwyn, P.A., and Schottenfeld, R.S.: Medical care for injection-drug users with human immunodeficiency virus infection. New England Journal of Medicine 331(7):450-459, 1994.

O'Connor, P.G., Molde, S., Henry, S., Shockcor, W.T., et al.: Human immunodeficiency virus infection in intravenous drug users: a model for primary care. American Journal of Medicine 93(4):382-386, 1992.

O'Dowd, M.A., Natali, C., Orr, D., and McKegney, F.P.: Characteristics of patients attending an HIV-related psychiatric clinic. Hospital and Community Psychiatry 42(6):615-619, 1991.

Office of Technology Assessment.: The effectiveness of drug abuse treatment: implications for controlling AIDS/HIV infection. Washington, D.C.: U.S. Government Printing Office, 1990.

Onorato, I.M., and Markowitz, L.E.: Immunizations, vaccine-preventable diseases, and HIV infection. In AIDS and other manifestations of HIV infection. 2nd ed. New York: Raven Press, 1992. pp. 671-681.

Orlander, J.D., Samet, J.H., Kazis, L., Freedberg, K.A., et al.: Improving medical residents' attitudes toward HIV-infected persons through training in an HIV staging and triage clinic. Academic Medicine 69(12):1001-1003, 1994.

Osmond, D., Charlebois, E., Lang, W., Shiboski, S., et al.: Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983-1993. Journal of the American Medical Association 271(14):1083-1087, 1994.

Page, J.B., Lai, S.H., Chitwood, D.D., Klimas, N.G., et al.: HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. Lancet 335(8703):1439-1441, 1990.

Page, Y., Tardy, B., Zeni, F., Comtet, C., et al.: Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 337(8744):774-776, 1991.

Pantaleo, G., Graziosi, C., Demarest, J.F., Butini, L., et al.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362(6418):355-358, 1993.

Perez-Arce, P., Carr, K.D., and Sorensen, J.L.: Cultural issues in an outpatient program for stimulant abusers. Journal of Psychoactive Drugs 25(1):35-44, 1993.

Piette, J.D., Fleishman, J.A., Stein, M.D., Mor, V., et al.: Perceived needs and unmet needs for formal services among people with HIV disease. Journal of Community Health 18(1):11-23, 1993.

Price, R.W., and Brew, B.J.: The AIDS dementia complex. Journal of Infectious Diseases 158(5):1079-1083, 1988.

Pohl, M.: Neurocognitive impairment in alcoholics: review and comparison with cognitive impairment due to AIDS. (Issue title: AIDS and Substance Abuse.) Advances in Alcohol and Substance Abuse 7(2)107-116, ~~1987.~~

Rakower, D., and Galvin, T.A.: Nutrition in HIV infection. New York State Department of Health, AIDS Institute. 3(4):29, 1989.

Regier, D.A., Farmer, M.E., Rae, D.S., Locke, B.Z., et al.: Comorbidity of mental disorders with alcohol and other drug abuse. Results for the Epidemiological Catchment Area (ECA) Study. Journal of the American Medical Association 264(19):2511-2518, 1990.

Ross, H.E., Glaser, F.B., and Germanson, T.: The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Archives of General Psychiatry 45(11):1023-1031, 1988.

Rutherford, G.W., Lifson, A.R., Hessol, N.A., Darrow, W.W., et al.: Course of HIV-1 infection in a cohort of homosexual and bisexual men: an 11 year follow up study. British Medical Journal 301(6762):1183-1188, 1990.

Saag, M.S.: The natural history of HIV-1 infection. In: Broder, S., Merigan, T.C., and Bolognesi, D., eds. Textbook of AIDS Medicine. Baltimore: Williams & Wilkins, 1994a. pp. 45-53.

Saag, M.S.: What to do when zidovudine fails (editorial; comment). New England Journal of Medicine 330(10):706-707, 1994b.

Samet, J.H., Stein, M.D., and O'Connor, P.G.: Models of medical care of HIV-infected drug users. Archives of Internal Medicine, in press.

Samet, J.H., Libman, H., LaBelle, C., et al.: A model clinic for the initial evaluation and establishment of primary care for HIV-infected persons, unpublished study, 1994.

Samet, J.H., Libman, H., Steger, K.A., Dhawan, R.K., et al.: Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. American Journal of Medicine 92(5):495-502, 1992a.

Samet, J.H., Retondo, M.J., Freedberg, K.A., Stein, M.D., et al.: Factors associated with late initial presentation to primary medical care for human immunodeficiency virus-infected persons. Clinical Research 40:562A, 1992b.

Samet, J.H., Libman, H., Freedberg, K.A., and Craven, D.E.: Staging and triage of persons infected with human immunodeficiency virus at a municipal hospital. Clinical Research 39:608A, 1991.

Samet, J.H., Libman, H., LaBelle, C., Steger K., et al.: A model clinic for the initial evaluation and establishment of primary care for HIV-infected persons. Submitted for publication 1994.

Samuels, J.E., Hendrix, J., Hilton, M., Marantz, P.R., et al.: Zidovudine therapy in an inner city population. Journal of Acquired Immune Deficiency Syndrome 3(9):877-883, 1990.

Sande, M.A., Carpenter, C.C., Cobbs, C.G., Holmes, K.K., et al.: Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. Journal of the American Medical Association 270(21):2583-2589, 1993.

Sawyer, R.C., Brown, K.S., et al.: Evaluation of a possible pharmacologic interaction between rifabutin and methadone in HIV-seropositive injecting drug users (PO-B30-2197). Ninth International Conference on AIDS. Berlin, 1993.

Schilling, R.F., Schinke, S.P., Nichols, S.E., Zayas, L.H., et al.: Developing strategies for AIDS prevention research with black and Hispanic drug users. Public Health Reports 104(1):2-11, 1989.

Schleifer, S.J., Keller, S.E., Lombardo, J.M., Franklin, J.E., LaFarge, S., and Miller, S.I.: HIV-1 antibody reactivity in inner-city alcoholics (letter). Journal of the American Medical Association 262:2680-2681, ~~1993.~~ 1989.

Schneider, M.M., Hoepelman, A.I., Eeftinck Schattenkerk, J.K., Nielsen, T.L., et al.: A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. New England Journal of Medicine 327(26):1836-1841, 1992.

Schoenbaum, E.E., Hartel, D., Selwyn, P.A., Klein, R.S., et al.: Risk factors for human immunodeficiency virus infection in intravenous drug users. New England Journal of Medicine 321(13):874-879, 1989.

Schwartz, E.L., Brechbuhl, A.B., Kahl, P., Miller, M.A., et al.: Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. Journal of Acquired Immune Deficiency Syndrome 5(6):619-626, 1992.

Selwyn, P.A., Budner, N.S., Wasserman, W.C., and Arno, P.S.: Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Reports 108(4):492-500, 1993.

Selwyn, P.A., and O'Connor, P.G.: Diagnosis and treatment of substance users with HIV infection. Primary Care (Special issue: AIDS and HIV Infection in Office Practice) 19(1):119-156, 1992.

Selwyn, P.A., Alcabes, P., Hartel, D., Buono, D., et al.: Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection (published erratum appears in New England Journal of Medicine 328 (9):671). New England Journal of Medicine 327(24):1697-1703, 1992a.

Selwyn, P.A., Sckell, B.M., Alcabes, P., Friedland, G.H., et al.: High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy (published erratum appears in Journal of the American Medical Association 268(24):3434, see comments, 1992). Journal of the American Medical Association 268(4):504-509, 1992b.

Selwyn, P.A., Feingold, A.R., Iezza, A., Satyadeo, M., et al.: Primary care for patients with human immunodeficiency virus (HIV) infection in a methadone maintenance treatment program. Annals of Internal Medicine 111(9):761-763, 1989.

Sorenson, J.L., and Batki, S.L.: Management of psychosocial sequelae of HIV infections among drug users. In: Lowinson, J.H., Ruiz, P., and Millman, R.R., eds. Substance abuse: A Comprehensive Textbook. Baltimore: Williams & Wilkins 1992.

Spruance, S.L., Pavia, A.T., Peterson, D., Berry, A., et al.: Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb A1454-010 Study Group. Annals of Internal Medicine 120(5):360-368, 1994.

Stein, D.S., Graham, N.M., Park, L.P., Hoover, D.R., et al.: The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Annals of Internal Medicine 121(2):100-108, 1994.

Stein, M.D., Samet, J.H., and O'Connor, P.G.: The linkage of primary care services with substance abuse treatment: new opportunities for academic generalists. Journal of General Internal Medicine 8(2):106-107, 1993.

Stimmel, B., Vernace, S., and Schaffner, F.: Hepatitis B surface antigen and antibody. A prospective study in asymptomatic drug abusers. Journal of the American Medical Association 234(11):1135-1138, 1975.

Thomas, S.B., and Quinn, S.C.: The Tuskegee Syphilis Study, 1932 to 1972: implications for HIV education and AIDS risk education programs in the black community. American Journal of Public Health 81(11):1498-1505, 1991.

Tong, T.G., Pond, S.M., Kreek, M.J., Jaffery, N.F., et al.: Phenytoin-induced methadone withdrawal. Annals of Internal Medicine 94(3):349-351, 1981.

Umbricht-Schneiter, A., Ginn, D.H., Pabst, K.M., and Bigelow, G.E.: Providing medical care to methadone clinic patients: referral vs. on-site care. American Journal of Public Health 84(2):207-210, 1994.

Volberding, P.A., Lagakos, S.W., Koch, M.A., Pettinelli, C., et al.: Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. New England Journal of Medicine 322(14):941-949, 1990.

Ward, J.W., Bush, T.J., Perkins, H.A., Lieb, L.E., et al.: The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. New England Journal of Medicine 321(14):947-952, 1989.

Weiss, S. H.: Links between cocaine and retroviral infection. Journal of the American Medical Association 261(4):607-609, 1989.

Wiegand, M., Moller, A.A., Schreiber, W., Krieg, J.C., et al.: Alterations of nocturnal sleep in patients with HIV infection. Acta Neurologica Scandinavica 83(2):141-142, 1991.

Youle, M.S., Gazzard, B.G., Johnson, M.A., Cooper, D.A., et al.: Effects of high-dose oral acyclovir on herpes virus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group (published erratum appears in AIDS 8(6): following 859). AIDS 8(5):641-649, 1994.

Table of Contents

Initiatives | Funding | Home

	U.S. Department of Health and Human Services
	Substance Abuse and Mental Health Services Administration
	Center for Mental Health Services
	Center for Substance Abuse Prevention
	Center for Substance Abuse Treatment

(800) 729-6686

TDD: (800) 487-4889

Español: (877) 767-8432

SAMHSA Home | Freedom of Information Act | Department of Health and Human Services | The White House | USA.gov

Treatment for HIV-Infected Alcohol and Other Drug Abusers Treatment Improvement Protocol (TIP) Series: 15

Appendix A -- Bibliography

Treatment for HIV-Infected Alcohol and Other Drug Abusers
Treatment Improvement Protocol (TIP) Series: 15